Gastric Sleeve and GLP-1 Weight Loss: Understanding the Connection
Obesity is a complex condition with many causes, including genetics, environmental factors, medications, and lifestyle choices. Many people struggle for years to lose weight and keep it off. Bariatric surgery and medications called GLP-1s (glucagon-like peptide-1 receptor agonists) are popular options for treating obesity. Learn about these two treatment approaches and their effectiveness at achieving sustainable weight loss.New Study Highlights Superiority of Bariatric Surgery Over GLP-1 Medications for Sustained Weight Loss
A new real-world study presented at the ASMBS 2025 Annual Meeting compares outcomes between GLP-1 medications (such as semaglutide and tirzepatide) and bariatric surgery. The findings show that patients who underwent sleeve gastrectomy or gastric bypass lost approximately five times more weight than those who took GLP-1 medications. This study highlights the effectiveness of bariatric surgery in achieving sustained weight loss, a crucial factor in managing obesity.Weight Regain and Insufficient Weight Loss After Metabolic Bariatric Surgery
Weight regain and insufficient weight loss are essential problems after metabolic bariatric surgery (MBS) in people living with obesity. Changes in the level of glucagon-like peptide-1 (GLP-1) secreted from the gut after bariatric surgery are one of the reasons for weight regain. Understanding these changes can help patients and healthcare providers develop strategies to prevent weight regain and maintain weight loss.Using GLP-1 Weight Loss Injections After Gastric Sleeve Surgery
Quick Answer: Weight loss injections can be prescribed after gastric sleeves surgery in appropriate candidates when evaluated and monitored by a bariatric surgery team. FDA-approved weight loss injections include semaglutide (Wegovy) and tirzepatide (Zepbound), which are GLP-1 and dual GIP/GLP-1 receptor agonists administered subcutaneously. These medications are typically considered after the patient has reached a stable weight loss plateau.Comparing Gastric Sleeve and GLP-1 Weight Loss Medications
A recent study compared the effectiveness of liraglutide (a GLP-1 receptor agonist) with a control group in patients who had less than 20% weight loss after gastric bypass or sleeve gastrectomy. The results showed that liraglutide resulted in 8.8% weight loss over 6 months compared to 0.5% in patients in the control group. However, the trial was constrained by its small sample size, short duration, and potential biases.Combining Medical Weight Loss and Bariatric Surgery for Better Outcomes
